Trivalent recombinant protein vaccine induces cross-neutralization against XBB lineage and JN.1 subvariants: preclinical and phase 1 clinical trials

Trivalent recombinant protein vaccine induces cross-neutralization against XBB lineage and JN.1 subvariants: preclinical and phase 1 clinical trials

Abstract The immune escape capacities of XBB variants necessitate the authorization of vaccines with these antigens. In this study, we produce three recombinant trimeric proteins from the RBD sequences of Delta, BA.5, and XBB.1.5, formulating a trivalent vaccine (Tri-Vac) with an MF59-like adjuvant...

Full description

Saved in:
Bibliographic Details
Main Authors: Jingyun Yang, Weiqi Hong, Huashan Shi, Cai He, Hong Lei, Yanan Zhou, Hao Yang, Aqu Alu, Zimin Chen, Yun Yang, Wenhai Yu, Cong Tang, Junbin Wang, Bai Li, Qing Huang, Jiong Li, Li Yang, Wei Wang, Guobo Shen, Jinliang Yang, Zhiwei Zhao, Xiangrong Song, Zhaoming Su, Yuquan Wei, Qiangming Sun, Shuaiyao Lu, Zhenling Wang, Youchun Wang, Guangwen Lu, Weimin Li, Xiawei Wei
Format: Article
Language:English
Published: Nature Portfolio 2024-12-01
Series:Nature Communications
Online Access:https://doi.org/10.1038/s41467-024-55087-z
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1038/s41467-024-55087-z

Similar Items